样式: 排序: IF: - GO 导出 标记为已读
-
Patient-reported outcomes on sleep quality and circadian rhythm during treatment with intravenous ketamine for treatment-resistant depression Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2024-03-04 Raymond Yan, Tyler Marshall, Atul Khullar, Travis Nagle, Jake Knowles, Mai Malkin, Brittany Chubbs, Jennifer Swainson
Background:Intravenous (IV) ketamine is a rapid acting antidepressant used primarily for treatment-resistant depression (TRD). It has been suggested that IV ketamine’s rapid antidepressant effects may be partially mediated via improved sleep and changes to the circadian rhythm.Objectives:This study explores IV ketamine’s association with changes in patient-reported sleep quality and circadian rhythm
-
Drug safety in older patients with alcohol use disorder: a retrospective cohort study Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2024-02-21 Sebastian Schröder, Martin Schulze Westhoff, Tabea Pfister, Johanna Seifert, Stefan Bleich, Felix Koop, Phileas Johannes Proskynitopoulos, Alexander Glahn, Johannes Heck
Background:Older patients with alcohol use disorder are at particular risk of developing adverse drug reactions due to multimorbidity, polypharmacy, and altered organ function.Objectives:In this study, we investigated the frequency and characteristics of potentially serious alcohol–medication interactions, potentially inappropriate medications (PIMs) for older adults, and potential drug–drug interactions
-
Patients’ awareness of recovery mediates the link between clinical and level of functional remission in schizophrenia to a larger extent in those treated with long-acting antipsychotics Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2024-02-16 Jasmina Mallet, Clément Dondé, Caroline Dubertret, Philip Gorwood
Background:Clinical remission is a step towards functional remission for subjects with schizophrenia. While recovery is both a subjective personal journey and a clinical outcome to be targeted, data on patient self-rated outcomes are scarce.Objectives:(i) To determine the extent to which the association between clinical and functional remission is mediated by the subjective experience of recovery as
-
Monoclonal antibody precision therapy targeting inflammation for bipolar disorder: a narrative review Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2024-02-06 Shijin Wu, Yuyang Zhou
Bipolar disorder (BD) is a severe mental disorder with various hypotheses regarding its pathogenesis. This article provides a summary of numerous studies on the variations in inflammatory cytokine levels in patients with BD and the effects of treatment with antipsychotics, mood stabilizers, and antidepressants on these levels. In addition, patients with autoimmune diseases who use anti-inflammatory
-
A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-11-22 Shen He,Yimin Yu,Jingjing Huang,Jiahui Yin,Yajuan Niu,Yazhou Lu,Bin Wu,Maosheng Fang,Xue Wang,Zhiping Tao,Lehua Li,Kan Li,Yan Li,Xiujuan Ding,Yifeng Shen,Huafang Li
Background Almost one-third of patients with major depressive disorder (MDD) do not respond to conventional antidepressants, and new treatments for MDD are urgently needed. Objectives This phase IIb clinical trial was designed to evaluate the efficacy and safety of Anyu Peibo capsules in the treatment of adults with MDD. Design A multicenter, randomized, double-blind, placebo-controlled, parallel-group
-
Prevalence and predictors of inappropriate prescribing in outpatients with severe mental illness. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-11-22 Lisanne Koomen,Ilona van de Meent,Floor Elferink,Ingeborg Wilting,Wiepke Cahn
Background Potentially inappropriate prescribing (PIP) is frequent in geriatrics and results in an increased risk for adverse effects, morbidity, mortality and reduced quality of life. Research on PIP in psychiatry has mainly focused on elderly patients and inpatients. Objectives To determine the prevalence and the predictors of PIP of psychotropic medication in outpatients with severe mental illness
-
Psychosocial interventions to improve adherence in depressed and anxious older adults prescribed antidepressant pharmacotherapy: a scoping review. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-11-20 Sarah T Stahl,Joelle Kincman,Jordan F Karp,Marie Anne Gebara
Medication nonadherence in depressed and anxious older adults is prevalent and associated with non-response to antidepressant pharmacotherapy. Evidence-based options to improve medication adherence are limited in this population. To review the state of the literature on the types and efficacy of psychosocial interventions for improving antidepressant pharmacotherapy adherence in depressed and anxious
-
Optimizing treatment for older adults with depression. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-11-18 Maytinee Srifuengfung,Bethany R Tellor Pennington,Eric J Lenze
This review presents a comprehensive guide for optimizing medication management in older adults with depression within an outpatient setting. Medication optimization involves tailoring the antidepressant strategy to the individual, ensuring the administration of appropriate medications at optimal dosages. In the case of older adults, this process necessitates not only adjusting or changing antidepressants
-
Management of dyslipidaemia in individuals with severe mental illness: a population-based study in the Greater Copenhagen Area. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-11-17 Grimur Høgnason Mohr,Carlo Alberto Barcella,Mia Klinten Grand,Margit Kriegbaum,Volkert Siersma,Margaret K Hahn,Sri Mahavir Agarwal,Catrine Bakkedal,Lone Baandrup,Filip Krag Knop,Christen Lykkegaard Andersen,Bjørn Hylsebeck Ebdrup
Background Severe mental illness (SMI) is associated with increased cardiovascular risk. Dyslipidaemia is a potentially modifiable risk factor, which may be inadequately managed in patients with SMI. Objectives To assess management of dyslipidaemia in patients with SMI versus healthy controls (HCs) in 2005 and 2015. Design and methods Using Danish registers, we identified adult patients with SMI in
-
Efficacy of intraoperative subanesthetic dose of ketamine/esketamine in preventing postoperative cognitive dysfunction: a systematic review and meta-analysis. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-10-30 Na Zhou,Chengchuan Chen,Yubei Liu,Zhaolan Yu,Yanhua Chen
Background Postoperative cognitive dysfunction (POCD) is a common complication after anesthesia surgery, especially in older people, that can persist weeks or months after surgery as a short-term impairment of cognitive abilities, or even for a prolonged duration over years, potentially progressing into permanent cognitive dysfunction. However, the pathogenesis of POCD is not fully understood, and
-
Comparative effectiveness study of paliperidone palmitate 6-month with a real-world external comparator arm of paliperidone palmitate 1-month or 3-month in patients with schizophrenia. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-09-29 Ibrahim Turkoz,Joshua Wong,Benjamin Chee,Uzma Siddiqui,R Karl Knight,Ute Richarz,Christoph U Correll
Background The paliperidone palmitate 6-month (PP6M) long-acting injectable formulation is currently the longest dosing interval available for schizophrenia treatment. Objective To compare treatment outcomes between a real-world external comparator arm (ECA; NeuroBlu database) and the PP6M open-label extension (OLE) clinical trial arm. Methods The ECA comprised patients receiving PP 1-month (PP1M)
-
Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-09-27 Caiji Zheng,Haiyan Liu,Weifeng Tu,Lingyun Lin,Haiyun Xu
Background Previous studies reported higher incidences of venous thromboembolism and cardiovascular disease in schizophrenia patients and higher indicators of thrombosis, thrombocyte activation, and platelet dysfunction. Objectives To check if first-episode schizophrenia (FES) patients have a hypercoagulable state and determine whether acute and chronic antipsychotics have the same effect on blood
-
Ketamine for bipolar depression: an updated systematic review. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-09-26 Farhan Fancy,Sipan Haikazian,Danica E Johnson,David C J Chen-Li,Anastasia Levinta,Muhammad I Husain,Rodrigo B Mansur,Joshua D Rosenblat
Background The therapeutic potential of subanesthetic doses of ketamine appears promising in unipolar depression; however, its effectiveness in treating bipolar depression (BD) remains uncertain. Objective This systematic review aimed to summarize findings on the use of ketamine for the treatment of BD by assessing its efficacy, safety, and tolerability. Design Systematic review. Methods We conducted
-
History repeating: guidelines to address common problems in psychedelic science. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-09-25 Michiel van Elk,Eiko I Fried
Research in the last decade has expressed considerable optimism about the clinical potential of psychedelics for the treatment of mental disorders. This optimism is reflected in an increase in research papers, investments by pharmaceutical companies, patents, media coverage, as well as political and legislative changes. However, psychedelic science is facing serious challenges that threaten the validity
-
Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an in silico modelling study. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-09-13 James R O'Neill,David M Taylor,Mark A Horowitz
Gradual, hyperbolic tapering has been proposed as a method to reduce the risk of withdrawal effects and potential relapse of an underlying condition by minimising disruption of existing equilibria. We applied hyperbolic tapering principles in silico to long-acting aripiprazole to generate regimens for withdrawal in clinical practice. We derived thresholds for taper rates using existing studies and
-
Anticholinergic action is rarely a good thing. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-09-08 Delia Bishara
The evidence for the risks associated with anticholinergic agents has grown considerably in the last two decades. Not only are they associated with causing peripheral side effects such as dry mouth, blurred vision and constipation, but they can also cause central effects such as cognitive impairment; and more recently, they have consistently been linked with an increased risk of dementia and death
-
Preventing and treating delirium in clinical settings for older adults. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-09-08 Morgan Faeder,Elizabeth Hale,Daniel Hedayati,Alex Israel,Darcy Moschenross,Melanie Peterson,Ryan Peterson,Mariel Piechowicz,Jonathan Punzi,Priya Gopalan
Delirium is a serious consequence of many acute or worsening chronic medical conditions, a side effect of medications, and a precipitant of worsening functional and cognitive status in older adults. It is a syndrome characterized by fluctuations in cognition and impaired attention that develops over a short period of time in response to an underlying medical condition, a substance (prescribed, over
-
Antipsychotics and structural brain changes: could treatment adherence explain the discrepant findings? Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-09-08 Robin Emsley
Progressive structural brain changes are well documented in schizophrenia and have been linked to both illness progression and the extent of antipsychotic treatment exposure. Literature reporting longitudinal changes in brain structure in individuals with schizophrenia is selectively reviewed to assess the roles of illness, antipsychotic treatment, adherence and other factors in the genesis of these
-
The past, present and future of anticholinergic drugs. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-09-08 David Healy
In current medical practice, it is difficult to find any reports claiming that drugs that are primarily anticholinergic or those that have significant anticholinergic effects have any therapeutic benefits. These drugs fell into disrepute within the mental health field from the mid-1960s onwards, and their supposed problems extended to elsewhere in medicine after that. There is considerable evidence
-
Managing medical and psychiatric multimorbidity in older patients. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-08-30 David M Carlson,Brandon C Yarns
Aging increases susceptibility both to psychiatric and medical disorders through a variety of processes ranging from biochemical to pharmacologic to societal. Interactions between aging-related brain changes, emotional and psychological symptoms, and social factors contribute to multimorbidity - the presence of two or more chronic conditions in an individual - which requires a more patient-centered
-
Altered whole-brain resting-state functional connectivity and brain network topology in typhoon-related post-traumatic stress disorder. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-06-17 Hui Juan Chen,Jun Ke,Jie Qiu,Qiang Xu,Yuan Zhong,Guang Ming Lu,Yanglei Wu,Rongfeng Qi,Feng Chen
Background Altered resting-state functional connectivity has been found in patients with post-traumatic stress disorder (PTSD). However, the alteration of resting-state functional connectivity at whole-brain level in typhoon-traumatized individuals with PTSD remains largely unknown. Objectives To investigate changes in whole-brain resting-state functional connectivity and brain network topology in
-
The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-05-29 Ricarda Evens,Marianna Elisa Schmidt,Tomislav Majić,Timo Torsten Schmidt
Background Classic serotonergic psychedelics have anecdotally been reported to show a characteristic pattern of subacute effects that persist after the acute effects of the substance have subsided. These transient effects, sometimes labeled as the 'psychedelic afterglow', have been suggested to be associated with enhanced effectiveness of psychotherapeutic interventions in the subacute period. Objectives
-
Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-05-25 Vivian W L Tsang,Brendan Tao,Shannon Dames,Zach Walsh,Pam Kryskow
Background In the last few years, ketamine is becoming increasingly common in the treatment of mental health conditions, but there is a lack of safety data informing intramuscular and sublingual dosing in a community-focused group psychotherapy setting. The Roots To Thrive ketamine-assisted therapy (RTT-KaT) program is a unique 12-week RTT-KaT program with 12 community of practice (a form of group
-
High-dose olanzapine in treatment-resistant schizophrenia: a systematic review Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-05-11 Louisa Gannon, John Reynolds, Martin Mahon, Fiona Gaughran, John Lally
Background:Treatment-resistant schizophrenia (TRS) affects approximately 30% of people with schizophrenia. Clozapine is the gold standard treatment for TRS but is not always suitable, with a propor...
-
Outcomes of hyperbolic tapering of antidepressants Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-05-09 Jim van Os, Peter C. Groot
Background:In patients attempting to discontinue their antidepressant medication, there have been no prospective studies on patterns of withdrawal as a function of the rate of antidepressant reduct...
-
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-04-19 Femin Prasad, Riddhita De, Vittal Korann, Araba F. Chintoh, Gary Remington, Bjørn H. Ebdrup, Dan Siskind, Filip Krag Knop, Tina Vilsbøll, Anders Fink-Jensen, Margaret K. Hahn, Sri Mahavir Agarwal
Metformin is the currently accepted first-line treatment for antipsychotic-associated weight gain (AAWG). However, not all patients benefit from metformin. Glucagon-like peptide-1 receptor agonists...
-
Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-03-25 Mishal Qubad, Robert A. Bittner
Despite its enduring relevance as the single most effective and important evidence-based treatment for schizophrenia, underutilization of clozapine remains considerable. To a substantial degree, th...
-
Long-acting injectable antipsychotics for the treatment of bipolar disorder: evidence from mirror-image studies Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-03-25 Francesco Bartoli, Daniele Cavaleri, Christian Nasti, Dario Palpella, Pierluca Guzzi, Ilaria Riboldi, Cristina Crocamo, Sofia Pappa, Giuseppe Carrà
Clinical trials and real-world data have shown that long-acting injectable antipsychotics (LAIs) might be an effective therapeutic option also for people with bipolar disorder (BD). However, comple...
-
The role of flumazenil in generalised anxiety disorder: a pilot naturalistic open-label study with a focus on treatment resistance Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-03-15 Alexander T Gallo, Stephen Addis, Vlad Martyn, Hishani Ramanathan, Grace K Wilkerson, Kellie S Bennett, Sean D Hood, Hans Stampfer, Gary K Hulse
Background:Anxiety disorders are highly prevalent and chronic disorders with treatment resistance to current pharmacotherapies occurring in approximately one in three patients. It has been postulat...
-
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-03-06 Anya Ragnhildstveit, Jeremy Roscoe, Lisa C. Bass, Christopher L. Averill, Chadi G. Abdallah, Lynnette A. Averill
Posttraumatic stress disorder (PTSD) is a devastating condition, for which there are few pharmacological agents, often with a delayed onset of action and poor efficacy. Trauma-focused psychotherapi...
-
The place of long-acting injectable antipsychotics in the treatment of schizophrenia. Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-03-06 John M Kane,Jose M Rubio
-
Olanzapine for the treatment of ICU delirium: a systematic review and meta-analysis Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-02-20 Si Bo Liu, Shan Liu, Kai Gao, Guo Zhi Wu, Guo Zu, Jin Jie Liu
Background:As an atypical antipsychotic drug, olanzapine is one of the most commonly used drugs for delirium control. There are no systematic evaluations or meta-analyses of the efficacy and safety...
-
Serum cytokine variations among inpatients with major depression, bipolar disorder, and schizophrenia versus healthy controls: a prospective ‘true-to-life’ study Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-02-16 Antonio Augusto Schmitt Junior, Lucas Primo de Carvalho Alves, Barbara Larissa Padilha, Neusa Sica da Rocha
Background:There is increasing evidence of the association between chronic low-grade inflammation and severe mental illness (SMI). The objective of our study was to assess serum cytokine levels (SC...
-
Incidence of hyperthyroidism in patients with bipolar or schizoaffective disorder with or without lithium: 21-year follow-up from the LiSIE retrospective cohort study Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-02-09 Ingrid Lieber, Michael Ott, Robert Lundqvist, Mats Eliasson, Ursula Werneke
Background:Lithium-associated hyperthyroidism is much rarer than lithium-associated hypothyroidism. Yet, it may be of substantial clinical significance for affected individuals. For instance, lithi...
-
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-02-07 Fabrice Jollant, Romain Colle, Thi Mai Loan Nguyen, Emmanuelle Corruble, Alain M. Gardier, Martin Walter, Mocrane Abbar, Gerd Wagner
Background:More than 2% of the general population experience suicidal ideas each year and a large number of them will attempt suicide. Evidence-based therapeutic options to manage suicidal crisis a...
-
Enduring neurological sequelae of benzodiazepine use: an Internet survey Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2023-02-06 Christy Huff, A. J. Reid Finlayson, D. E. Foster, Peter R. Martin
Introduction:Benzodiazepine tapering and cessation has been associated with diverse symptom constellations of varying duration. Although described in the literature decades ago, the mechanistic und...
-
Clozapine for treatment resistance in early psychosis: a survey of UK clinicians’ training, knowledge and confidence Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-12-26 Ebenezer Oloyede, Bethany Mantell, Julie Williams, Serena Lai, Sameer Jauhar, David Taylor, James H. MacCabe, Robert Harland, Philip McGuire, Graham Blackman
Background:Clozapine is the only medication licenced for patients with psychosis that is resistant to conventional antipsychotic treatment. However, despite its effectiveness, it remains widely und...
-
Current perspectives on the epidemiology and burden of tardive dyskinesia: a focused review of the clinical situation in Japan Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-12-26 Yasuhiro Mori, Hiroyoshi Takeuchi, Yuichiro Tsutsumi
Tardive dyskinesia (TD) is a movement disorder that can develop with the use of dopamine receptor-blocking agents and is most commonly caused by antipsychotics. The use of antipsychotics is expandi...
-
Reasons for admission to a general medical hospital for patients taking clozapine Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-12-23 Siobhan Gee, Vasco Almeida, Adam Hughes, Isabel McMullen, David Taylor
Background:Clozapine is associated with a diverse range of side effects. In addition, patients prescribed clozapine commonly suffer with medical comorbidities.Objectives:This study aimed to charact...
-
Synthetic opioids: a review and clinical update Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-12-10 Abu Shafi, Alex J. Berry, Harry Sumnall, David M. Wood, Derek K. Tracy
The term ‘opioids’ refers to both the natural compounds (‘opiates’) which are extracted from the opium poppy plant (Papaver somniferum) and their semi-synthetic and synthetic derivatives. They all ...
-
Classic psychedelics, health behavior, and physical health Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-11-30 Otto Simonsson, Peter S. Hendricks, Richard Chambers, Walter Osika, Simon B. Goldberg
Background:Preliminary evidence suggests that classic psychedelics may be effective in the treatment of some psychiatric disorders, yet little remains known about their effects on health behavior a...
-
Increased amisulpride serum concentration in a patient treated with concomitant pregabalin and trazodone: a case report Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-11-30 Petr Potměšil, Lenka Kostýlková, Miloslav Kopeček
We report on the case of a 46-year-old woman with generalized anxiety disorder, paranoid personality disorder, and mild reduction in glomerular filtration rate (GFR). She was treated with pregabali...
-
Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-11-21 Sofia Pappa, Arturas Kalniunas, Hitendra Sharma, Ali Raza-Syed, Manzar Kamal, Fintan Larkin
Background:Cariprazine, a novel antipsychotic drug, is a partial agonist of dopamine D2/D3 receptors with preferential binding to the D3 receptor. There has been an increasing interest in cariprazi...
-
Increased left dorsolateral prefrontal cortex density following escitalopram intake during relearning: a randomized, placebo-controlled trial in healthy humans Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-11-17 Thomas Vanicek, Murray B. Reed, René Seiger, Godber M. Godbersen, Manfred Klöbl, Jakob Unterholzner, Benjamin Spurny-Dworak, Gregor Gryglewski, Patricia Handschuh, Clemens Schmidt, Christoph Kraus, Thomas Stimpfl, Rainer Rupprecht, Siegfried Kasper, Rupert Lanzenberger
Background:Serotonergic agents affect brain plasticity and reverse stress-induced dendritic atrophy in key fronto-limbic brain areas associated with learning and memory.Objectives:The aim of this s...
-
Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-11-15 Olivier Corbeil, Anne-Marie Essiambre, Laurent Béchard, Audrey-Anne Roy, Maxime Huot-Lavoie, Sébastien Brodeur, Ranjith Chandrasena, Chantale Thériault, Candice Crocker, Jean-Pierre Melun, Phil Tibbo, Marie-France Demers, Marc-André Roy
Background:Non-adherence to antipsychotics in schizophrenia is associated with an increased risk of psychotic relapse and hospitalization, a risk that is reduced with the use of long-acting injecta...
-
Acceptability of cannabidiol in patients with psychosis Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-10-25 Edward Chesney, Doga Lamper, Millie Lloyd, Dominic Oliver, Emily Hird, Philip McGuire
Background:Cannabidiol (CBD) is a promising novel candidate treatment for psychosis. It has a more benign side effect profile than antipsychotic medications, and being treated with CBD is not perce...
-
Pathophysiology, prognosis and treatment of tardive dyskinesia Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-10-21 Hiroyoshi Takeuchi, Yasuhiro Mori, Yuichiro Tsutsumi
Tardive dyskinesia (TD), a movement disorder associated with antipsychotics, most frequently affects the lower face and jaw muscles, but can also affect walking, breathing and use of the hands and ...
-
Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: a naturalistic mirror-image study Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-10-08 Cristiana Montemagni, Elisa Del Favero, Elena Cocuzza, Flavio Vischia, Paola Rocca
Background:Partial adherence to antipsychotics is the most common cause of relapses and rehospitalization in patients with schizophrenia (SZ), leading to higher health care costs and psychosocial d...
-
Clinical outcome analysis of patients with autism spectrum disorder: analysis from the UK Medical Cannabis Registry Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-09-20 Simon Erridge, Jess Kerr-Gaffney, Carl Holvey, Ross Coomber, Daniela A. Riano Barros, Urmila Bhoskar, Gracia Mwimba, Kavita Praveen, Chris Symeon, Simmi Sachdeva-Mohan, Mikael H. Sodergren, James J. Rucker
Introduction:Cannabis-based medicinal products (CBMPs) have been identified as a promising novel therapeutic for symptoms and comorbidities related to autism spectrum disorder (ASD). However, there...
-
Risperidone-induced priapism: a case report and literature review Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-08-24 Sarra Ateb, Taoufik Fourati, Hammadi Ben Rejeb, Dominique Januel, Noomane Bouaziz
Priapism is a rare pathological condition defined as painful and persistent penile erection that is unrelated to sexual stimulation. It can be classified as ischaemic or non-ischaemic. Many causes ...
-
Who is prescribed valproate and how carefully is this treatment reviewed in UK mental health services? Data from a clinical audit Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-08-23 Carol Paton, Leslie Citrome, Emilio Fernandez-Egea, Olivia Rendora, Thomas R.E. Barnes
Background:The licensed indications for valproate are narrow, yet this medication is commonly prescribed in mental health services.Objectives:To explore the target symptoms/behaviours for which val...
-
Antipsychotic polypharmacy and clozapine prescribing patterns: evolution and correlates before and after a psychiatric hospitalisation Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-08-23 Juliette Lagreula, Philippe de Timary, Laure Elens, Olivia Dalleur
Background:Antipsychotic polypharmacy (APP) prescribing and clozapine underuse are considered inappropriate prescribing in schizophrenia. Psychiatric hospitalisations may be suitable occasions to r...
-
Plasma levels of interleukin-6 and 3-methoxy-4-hydroxyphenylglycol and treatment with milnacipran in major depression Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-08-06 Reiji Yoshimura, Naomichi Okamoto, Atsuko Ikenouchi
Dear Editor,
-
Dose-response analysis of aripiprazole in patients with schizophrenia in Taiwan Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-07-30 Yun Tien, Hsiang-Ping Huang, Ding-Lieh Liao, Shang-Chien Huang
Background:Aripiprazole is a third-generation antipsychotic agent with acceptable efficacy and a good safety profile. Previous studies have indicated the therapeutic serum concentration of aripipra...
-
Comment on: Treatment strategies for clozapine-induced hypotension: A systematic review Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-07-19 Patrick M. Wieruszewski, Erica D. Wittwer, Sarah B. Leung, Jonathan G. Leung
We read with interest the systematic review by Tanzer et al.1 where they summarize 13 case reports and case series of patients with hypotension secondary to clozapine use. The authors should be commended for their efforts in seeking answers for this challenging adverse effect of clozapine. Although recommendations were provided for the management of orthostasis in ambulatory patients in this context
-
Olanzapine long-acting injection, discontinuation rates and reasons for discontinuation: 10 years’ experience at a UK high-secure hospital Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-07-18 Azizah Attard, John Wakelam, Josephine Broyd, David Taylor, Jonathan Hafferty
Background:Olanzapine pamoate has been shown to be an effective second-generation long-acting injection. Its popularity has possibly been adversely affected by the rare incidence of post-injection ...
-
Exercise interventions to reduce anxiety in mid-life and late-life anxiety disorders and subthreshold anxiety disorder: a systematic review Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-07-07 Terence W.H. Chong, Scherazad Kootar, Helen Wilding, Sarah Berriman, Eleanor Curran, Kay L. Cox, Alex Bahar-Fuchs, Ruth Peters, Kaarin J. Anstey, Christina Bryant, Nicola T. Lautenschlager
Background:Anxiety disorders are highly prevalent and cause significant distress, disability, and cost. Medication adverse effects and interactions increase in mid-life and late-life, highlighting ...
-
Vortioxetine as adjunctive therapy in the treatment of schizophrenia Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-07-05 Sofia Redaelli, Lilla Porffy, Ebenezer Oloyede, Olubanke Dzahini, Gabriella Lewis, Maria Lobo, Eromona Whiskey, Sukhi S. Shergill
Background:The evidence for safe and effective interventions to treat the negative and cognitive symptoms of schizophrenia is lacking.Objectives:Vortioxetine is a novel antidepressant that has been...
-
Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-06-30 Mark J. Millan
Generalized anxiety disorder (GAD), the most frequently diagnosed form of anxiety, is usually treated by cognitive-behavioural approaches or medication; in particular, benzodiazepines (acutely) and serotonin or serotonin/noradrenaline reuptake inhibitors (long term). Efficacy, compliance, and acceptability are, however, far from ideal, reinforcing interest in alternative options. Agomelatine, clinically
-
Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis Ther. Adv. Psychopharmacol. (IF 4.2) Pub Date : 2022-06-24 Maximilian Huhn, Thomas Arndt, Johannes Schneider-Thoma, Stefan Leucht
Background: Antipsychotics are the treatment of choice in the therapy of schizophrenia. These drugs can be associated with changes in heart rate, but this question has never been examined systematically. Objective: We aimed to analyse changes in heart rate during treatment with antipsychotics using the frequency of tachycardia and bradycardia events. Design: For this systematic review and meta-analysis